Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Melphalan 140 mg/m is Safe and Effective for Frail and Older Multiple Myeloma Patients With Comparable Rates of Minimal Residual Disease Negativity.
Clin Lymphoma Myeloma Leuk
February 2025
Department of Hematology and Oncology, University Hospitals Seidman Cancer Center, Cleveland, OH; Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, OH.
Background: Despite therapeutic advances, multiple myeloma (MM) remains challenging to treat effectively. High-dose melphalan (Mel200) with autologous stem cell transplantation (ASCT) is the standard treatment for transplant-eligible patients. Reduced-dose melphalan (Mel140) is an alternative for older or frail patients, yet its efficacy data remain unclear.
View Article and Find Full Text PDFA Case of Multiple Myeloma in a Patient with Birt-Hogg-Dube Syndrome.
Intern Med
March 2025
Department of Hematology, Institute of Medicine, University of Tsukuba, Japan.
Birt-Hogg-Dubé syndrome (BHDS) is an autosomal dominant disease caused by germline folliculin (FLCN) mutations and it is characterized by skin folliculomas, pulmonary cysts, and renal cell carcinomas (RCC). We herein report the first case of a female patient with BHDS who was diagnosed with multiple myeloma. Daratumumab-based treatment was effective, and the patient remained responsive for over three years.
View Article and Find Full Text PDFBCL2 inhibition for multiple myeloma and AL amyloidosis.
Br J Haematol
March 2025
Hematology and Medical Oncology, Winship Cancer Institute, Emory University, Atlanta, Georgia, USA.
Despite the development of novel treatments, multiple myeloma (MM) and light-chain (AL) amyloidosis remain incurable diseases. BCL2 inhibitors are a class of drugs under development for plasma cell disorders, with strong data supporting their use, particularly in patients with MM and AL amyloidosis harbouring the t(11;14). Venetoclax, the most extensively studied BCL2-specific inhibitor, was initially designed and evaluated for other malignant blood disorders.
View Article and Find Full Text PDFMonumen-TAL progress in the treatment of relapsed multiple myeloma.
Lancet Haematol
March 2025
Division of Hematology/Oncology, University of Alabama at Birmingham, Birmingham, AL, USA; O'Neal Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, AL, USA. Electronic address:
Background: Talquetamab is the first GPRC5D × CD3 bispecific antibody approved for relapsed or refractory multiple myeloma. In phase 1 of the MonumenTAL-1 study, initial results of subcutaneous talquetamab 0·4 mg/kg once a week and 0·8 mg/kg every 2 weeks showed preliminary clinical activity. We describe safety and activity results in patients treated with talquetamab, including patients who had received previous T-cell redirection therapy (TCR).
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!